AstraZeneca and Daiichi Sankyo ... endocrine therapy in the metastatic setting. Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy based on the ...
AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo. The Anglo-Swedish pharmaceutical ...
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
Following this approval for Enhertu in the U.S., AstraZeneca is due $175 million ... IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for ...
Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...
AstraZeneca Plc reported better-than-expected profit and revenue in the fourth quarter and forecast further gains, helped by the UK drugmaker’s blockbuster cancer drugs.
By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.
India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...
Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression ... as noted in a press release from Daiichi Sankyo and AstraZeneca, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results